Manulife Financial (MFC, Life & Health Insurance) Stock Valuation & Fair Value Fairly valued
Manulife Financial (MFC, Life & Health Insurance) trades at a blended P/E of 14.1, about 6% below its historical normal valuation, with a forward growth estimate of 11.0% and a PEG of 1.27. Analysts' one-year estimates have been hit 82% of the time.
No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.
- Price $43.60 at the 2026-09-23 close, 0.2% above the 20-day average ($43.50) and 0.4% above the 50-day ($43.41).
- RSI (14) at 51.0.
- 52-week range $29.84 to $44.59: the price is 2.2% below the high and 46.1% above the low.
The Street vs SeerForecast
Wall Street's mean price target for MFC is $34.82 across 1 analysts, 20.1% below the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.
Valuation flags
- No notable valuation flags.
Verdict history
tickerseer's rating has been fairly valued since 2026-09-19.
Ratings recorded live since 2026-09-21. Earlier points apply today's valuation rules to the metrics tickerseer archived that week.
Frequently asked questions
Is Manulife Financial stock overvalued?
At a blended P/E of 14.1 versus its historical normal P/E of 15.0, Manulife Financial trades about 6% below its typical valuation, with a PEG of 1.27 on 11.0% forward growth. tickerseer currently rates it fairly valued.
What is Manulife Financial's fair value and PEG?
Manulife Financial trades at a blended P/E of 14.1 against a historical normal P/E of 15.0, a PEG of 1.27, and a forward growth estimate of 11.0%.
Has tickerseer's rating of Manulife Financial changed?
tickerseer's rating has been fairly valued since 2026-09-19.
What is the analyst price target for Manulife Financial?
The mean Wall Street price target for Manulife Financial is $34.82 across 1 analysts, 20.1% below the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Life & Health Insurance. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.